GLP-1 Microdosing: What Telehealth Providers Advertise

Direct answer

Some telehealth providers currently advertise GLP-1 “microdosing” or lower-dose programs, but microdosing is not a standardized product category across providers. The term can refer to different compounded products, different provider-defined dose strategies, different treatment goals, and different commercial terms. RightFit therefore records the exact provider language, formulation, preparation type, price, commitment, included services, and regulatory status instead of assuming every microdose program means the same thing.

What providers are advertising now

Belle currently lists a program named Compounded Tirzepatide Microdose in its treatment catalog. The current Belle listing shows a three-month supply at an effective $99 per month. RightFit’s structured record keeps that amount attached to the three-month commitment rather than presenting $99 as an unrestricted month-to-month price.

Shed also currently markets a Microdose GLP-1 program. Its dedicated product page describes the program as lower-than-standard doses of compounded injectable semaglutide or tirzepatide and currently displays a starting price of $149. Shed uses provider-led and wellness-oriented language around the program. Those descriptions are provider marketing claims and should be attributed to Shed rather than converted into independent RightFit conclusions about benefits or outcomes.

Why the word “microdose” needs context

Unlike a brand name or an FDA-approved dosage form, “microdose” by itself does not tell a reader exactly what product is being offered. One provider may use the term for compounded tirzepatide, another for compounded semaglutide, and another may apply it to a broader lower-dose wellness program. Even when two providers use the same active ingredient, their formulations, pharmacies, packaging, clinical protocols, program goals, and billing structures can differ.

For that reason, RightFit should never merge programs simply because both use microdosing language. The program name is useful for discovery, but the comparison needs to be built from the underlying fields.

Microdosing does not change compounded-drug regulatory status

A compounded GLP-1 remains a compounded drug regardless of whether a provider describes the program as a microdose, starter approach, maintenance approach, longevity option, or lower-dose plan. FDA states that compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.

That distinction matters because marketing language can make two products sound more similar than their regulatory status actually is. RightFit should not describe a compounded microdose program as an FDA-approved microdose version of an approved branded medication unless an FDA-approved product and label actually support that description.

Lower-dose marketing is not proof of lower risk

Some provider pages suggest that a lower-dose approach may be gentler or may reduce side effects. RightFit can report that a provider makes those claims, but it should not adopt them as established facts for the provider’s compounded program. The correct comparison is between what the provider says, what the source establishes about the product, and what regulators or high-quality evidence establish about safety and effectiveness.

FDA has separately warned about dosing errors involving compounded injectable semaglutide and has reported concerns with compounded semaglutide and tirzepatide dosing outside approved-drug labeling. That regulatory context is especially important when a program’s marketing centers on dose strategy. RightFit should not provide self-dosing instructions, conversion formulas, titration schedules, or recommendations about how much medication a person should use.

What RightFit can compare reliably

• The provider and exact program name.
• The active ingredient when the provider identifies it.
• Whether the product is manufactured or compounded.
• The formulation and route when disclosed.
• The provider’s own description of the lower-dose or microdose approach.
• The current advertised price and whether it is promotional or standard.
• Any minimum commitment, prepayment requirement, or starter-period condition.
• Whether clinical care, shipping, membership, or other services are included or charged separately.
• The source URL and last verification date.
• The regulatory category of the underlying product.
• Program-level state availability only where a current source supports it.

What RightFit will not infer

RightFit will not infer that two microdose programs are clinically equivalent because they use the same marketing term. It will not claim that microdosing is safer, more effective, easier to tolerate, or appropriate for a particular person based only on provider marketing. It will not treat a lower advertised dose as evidence of a lower total treatment risk, and it will not recommend a microdose program over a standard program.

RightFit also will not assume that a compounded product is a generic, copy, or equivalent version of an FDA-approved brand. Product identity, preparation type, and regulatory status stay attached to the underlying program record.

Belle: how the current commercial terms should be read

Belle’s current catalog provides a useful example of why commitment terms belong beside the monthly-looking price. The microdose tirzepatide listing shows $99 per month but also identifies a three-month supply. RightFit therefore stores the price with the three-month eligibility term. A reader comparing Belle with a month-to-month program should not treat both monthly figures as though the commitment is identical.

The Belle record also identifies the preparation as compounded tirzepatide. That means the program belongs in a compounded-product comparison rather than inheriting the approval status, branded labeling, or clinical claims of an FDA-approved tirzepatide product.

Shed: why provider language and structured data should remain separate

Shed’s current microdose product page gives RightFit a second example of the term being used as a provider-defined program category. Shed describes lower-than-standard doses of compounded injectable semaglutide or tirzepatide and advertises a starting amount. It also markets broader wellness goals around the program.

RightFit can preserve those facts as attributed provider descriptions while keeping its structured medication records conservative. If the site does not yet have a verified, product-specific structured row for a Shed microdose formulation, the editorial page can explain what Shed advertises without inventing a structured program record. Editorial evidence and structured catalog evidence should move together only when the source supports all required fields.

“Starting at” still needs the same pricing discipline

A starting microdose price is not necessarily the recurring price for every formulation, dose, state, term, or patient. The amount can be promotional, tied to a minimum commitment, limited to one ingredient, or followed by a different recurring amount. RightFit should capture the exact pricing qualifier and avoid converting “starting at” into a universal monthly cost.

This is the same rule used across the wider telehealth pricing catalog: the displayed amount is useful only when the billing period, commitment, eligibility, and included services are also understood.

State availability should be verified at the program level

A provider operating broadly across the United States does not prove that every compounded microdose program is available in every state. Provider licensure, pharmacy reach, the formulation being dispensed, and provider policy can all affect availability. RightFit therefore leaves unverified state combinations blank rather than filling them from a provider’s general footprint.

A practical comparison checklist

• What exact medication or formulation is the provider calling a microdose?
• Is the product compounded or an FDA-approved manufactured drug?
• Does the provider identify semaglutide, tirzepatide, or another ingredient?
• Is the price standard, promotional, or only a starting amount?
• Does the price require multiple months of commitment or prepayment?
• Are membership, consultation, labs, and shipping included?
• What pharmacy or fulfillment information does the provider disclose?
• Is the exact program verified in the reader’s state?
• What health or wellness claims does the provider make, and are those claims clearly attributed?
• When was the provider page last checked?

Why RightFit avoids dose-by-dose instructions

The purpose of this guide is to explain how telehealth companies market and price microdose programs, not to teach a reader how to dose a prescription medication. Exact dosing and titration depend on the medication, formulation, concentration, clinical history, and prescriber instructions. Compounded products can also differ in concentration and packaging, which makes generic conversion advice especially inappropriate.

For comparison purposes, RightFit may record a provider-published dose description when it helps identify the commercial program. It should not translate that information into personal dosing advice or suggest that a reader copy a protocol from another provider.

Microdose marketing can target goals other than large weight loss

Current provider marketing shows that microdose programs are sometimes positioned around maintenance, modest weight-management goals, appetite support, wellness, energy, metabolism, or longevity rather than the larger weight-loss claims commonly associated with standard GLP-1 marketing. Those positioning choices are useful for describing how the market is evolving, but they are not independent evidence that the advertised outcomes will occur.

RightFit can compare the stated program goal as a marketing attribute while keeping clinical-effectiveness claims separate. A provider’s stated target audience should not become a medical recommendation from RightFit.

Source freshness matters in this category

Microdose offers can change quickly. Providers can alter introductory pricing, rename a program, switch the ingredient being highlighted, change a minimum term, or revise the claims on a landing page. A useful comparison therefore needs a last-verified date and should favor the provider’s current product or treatment page over old campaign pages, affiliate pages, search snippets, or third-party summaries.

When two first-party provider pages conflict, RightFit should retain the conflict for review instead of choosing whichever number looks more attractive. That same conservative rule already applies to other pricing conflicts in the RightFit catalog.

How microdose programs fit into the broader GLP-1 comparison

Microdose programs should be one filter or program attribute within the larger GLP-1 market, not a separate universe that erases the medication underneath. A useful comparison still starts with ingredient, formulation, preparation type, provider, regulatory status, state availability, price structure, fees, and commitment.

That approach lets readers understand what a provider is actually selling without RightFit deciding whether a lower-dose strategy is clinically preferable. It also makes it easier to identify when two apparently similar microdose offers are commercially or regulatorily different.

Bottom line

GLP-1 microdosing is a real and growing telehealth marketing category, but the term does not have one provider-independent meaning. Belle currently advertises a compounded tirzepatide microdose program with a three-month pricing structure, while Shed advertises lower-dose compounded semaglutide or tirzepatide through its own microdose program. Those examples show why the label alone is not enough.

RightFit’s role is to document the exact product, provider language, commercial terms, current source, and regulatory status, then let readers compare those facts. It should not turn microdose marketing into dosing advice, a safety claim, an effectiveness claim, or a recommendation about which treatment strategy is right for an individual.